Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A

 Published On: Sep, 2013 |    No of Pages: 44 |  Published By: MP Advisors | Format: PDF
Request Free Sample

The report provides an overview of the therapies for Multiple Myeloma (Newly diagnosed - NDMM and relapsed/ refractory - RRMM), unmet need, and limitations of the current standard of care (SoC) for relapsed and refractory MM pts. The report highlights the competition and commercial opportunity in pursuing this therapy area – Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them.

Detailed financial and competitive analysis of the companies leading in this field for this indication – Celgene, Amgen (post-acquisition of Onyx pharma), and MorphoSys are available within this full report. Key M&A activities that have taken place in this area in the last 5 years and a list of products in early /late-stages of development available for in-licensing are highlighted in the report. This report is built using primary and secondary research data and in-house proprietary database.

Reasons to buy the report

Useful for investors, Scientists, Business development managers of Pharma companies with focus in oncology to address the following-
• What are the opportunities or new approaches to be deployed in the R&D of the company?
• List of validated and new targets
• In-licensing opportunities – Is the way to go forward and be in the race?
• Commercial opportunity and companies’ valuation.


• Overview of the Disease and Unmet need
• Drugs in the pipeline: NDMM & RRMM – Mechanism of Action (MoA) and Clinical Stage of development
  Comparative Clinical data of Late-stage Pipeline in RRMM and NDDM
  Ongoing Clinical trial Details of Key Drugs in Pipeline
• Key milestones
• MPA view on the Future of the drugs in the late-stage pipeline
 Launch Timeline and Commercial Opportunity of Late-stage pipeline
 M&A and Licensing deals in the last 5 years
 In-licensing and/or M&A Opportunity
• Detailed Company analysis includes Clinical data of drugs, Milestones, and Valuation – Amgen (AMGN), Celgene (CELG), and MorphoSys (MOR)

1. Executive Summary
2. Investment Drivers of The Select Companies Covered
3. Multiple Myeloma (MM)
3.1 Disease Overview
3.2 Current Standard of Care
3.2.1 Relapsed and/or Refractory Multiple Myeloma (RRMM)
a Competitive landscape – RRMM
b Data Comparison – RRMM
3.2.2 Newly Diagnosed Multiple Myeloma (NDMM)
a Competitive landscape – NDMM
b Data Comparison – NDMM
4. Novel Targets including Monoclonal Antibodies And Small Molecules Offer In-Licensing Opportunity
4.1 Overview of Targets involved
4.2 Late-stage pipeline – Small Molecules
4.2.1 Kyprolis (carfilzomib)
4.2.2 POMALYST / IMNOVID (pomalidomide)
4.2.3 Ixazomib (MLN9708)
4.2.4 Panobinostat
4.2.5 Obatoclax
4.2.6 SNS01-T
4.2.7 Oprozomib
4.3 Late-stage pipeline – Monoclonal Antibodies
4.3.1 Elotuzumab
4.3.2 Siltuximab
4.3.3 Daratumumab
4.3.4 MOR202
5. Ongoing Clinical Trial Details of Key Drugs in the Pipeline
6. Key Milestones
7. MPA View on the Future of the Drugs in the Late-Stage pipeline
7.1 Launch Timeline and Commercial Opportunity of Late-stage Pipeline (RRMM and NDMM)
7.2 Drivers of M&A / Licensing Deals in MM
7.2.1 Select M&A Deals in Last 5 Years – 2007 to 2012
7.2.2 Select Licensing Deals in Last 5 Years – 2007 to 2012
7.2.3 M&A and Licensing Deals Opportunity
8. Detailed Company Analysis (incl. Clinical Data of Drugs, Milestones, and Valuation)
8.1 Amgen (AMGN, Post-acquisition of Onyx pharma)
8.1.1 Investment Drivers
8.1.2 Longer-term growth
a Acquisition of Onyx and its pipeline discussion
8.1.3 Late-stage pipeline
a Denosumab label expansion
b AMG 145 – Data presented at ESC 2013 and its comparison with REGN/SNY’s REGN727/SAR236553
c Collaboration agreement with Servier
d Talimogene laherparepvec (T-VEC)
e Trebananib (AMG 386)
8.1.4 Opportunity in Emerging market and Expansion in other Geographies
8.1.5 Key Milestones
8.1.6 NPV Valuation
8.2 Celgene (CELG)
8.2.1 Investment Drivers
8.2.2 Growth from Marketed products and Label expansion
a Revlimid – Geographic expansion and Generic threat after 2019
b Pomalyst – Current market scenario and competition to Kyprolis
c ABRAXANE – Label expansion
d Vidaza – Oral formulation and Generic entry in the US market
e Inflammation pipeline to start contributing to sales by 2014
f Novel Early stage products
8.2.3 Key Milestones
8.2.4 NPV Valuation
8.3 MorphoSyS
8.3.1 Investment Drivers
8.3.2 Recent Alliances
a. MOR / CELG for MOR202 (PhI/II, RRMM, anti-CD38 mAb)
b. MOR/ GSK for MOR103 (PhII, RA, anti-GM-CSF mAb)
8.3.3 Clinical Data from partnered pipeline products in 2H13 and Beyond
a. Bimagrumab (BYM338, PhII, COPD, Cancer, ActRIIB, sIBM)
b. BHQ880 (PhII, MM, anti-DKK-1 mAb)
c. Gantenerumab (IgG, PhIII, Alzheimer’s disease)
8.3.4 Other Partnered programs
8.3.5 Novel proprietary technology platforms
8.3.6 Key Milestones
8.3.7 NPV Valuation

If the above report does not have the information suitable for your business, we can provide custom research that can be lucrative for your business or enhance your profession.